IRMD Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
IRadimed Corp (IRMD) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company has shown strong financial performance in the latest quarter, with significant YoY growth in revenue, net income, and EPS. Analysts have raised price targets to $120, citing strong execution and confidence in the business. The technical indicators suggest bullish momentum with moving averages in alignment and a positive MACD. While there are no recent news catalysts or significant trading trends, the options data indicates a neutral to slightly bullish sentiment. Considering the investor's profile and the company's solid fundamentals, IRMD is a suitable long-term investment.
The technical indicators for IRMD are bullish. The MACD histogram is positive and contracting, suggesting upward momentum. The RSI is neutral at 38.761, indicating no overbought or oversold conditions. Moving averages are aligned bullishly (SMA_5 > SMA_20 > SMA_200). Key support is at 98.772, and resistance is at 105.9. The stock is trading near support levels, which could provide a good entry point.
Analysts have raised price targets to $120, citing strong Q4 results and confidence in the 3870 pump launch.
Financial performance shows robust growth in revenue, net income, and EPS.
Bullish technical indicators with aligned moving averages.
Gross margin has slightly decreased YoY (-1.41%).
No recent news or significant trading trends from hedge funds or insiders.
Congress trading data is unavailable, and options data shows neutral sentiment.
In Q4 2025, IRMD reported a 17.03% YoY increase in revenue to $22.69M, a 25.17% YoY increase in net income to $6.44M, and a 25% YoY increase in EPS to $0.50. However, gross margin dropped slightly by 1.41% YoY to 75.06%. Overall, the financials indicate strong growth and profitability.
Analysts from Lake Street and Roth Capital have raised their price targets to $120, maintaining Buy ratings. They cite strong Q4 results, higher forward estimates, and confidence in the 3870 pump launch as reasons for their optimism.
